Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617813 | 1.00 | AR (0.42) | ARSIRT6TMEM97HDAC3HDAC1 | |
| SCHEMBL2122485 | 1.00 | AR (0.42) | ARSIRT6TMEM97HDAC3HDAC1 | |
| SCHEMBL2119279 | 0.92 | AR (0.44) | ARSIRT6HDAC3HDAC1HDAC2 | |
| SCHEMBL2617767 | 0.92 | AR (0.44) | ARSIRT6HDAC3HDAC1HDAC2 | |
| SCHEMBL2617843 | 0.92 | AR (0.44) | ARSIRT6HDAC3HDAC1HDAC2 | |
| SCHEMBL2617807 | 0.91 | CCNC (0.42) | ARSIRT6TMEM97HDAC3HDAC1 | |
| SCHEMBL2118016 | 0.91 | CCNC (0.42) | ARSIRT6TMEM97HDAC3HDAC1 | |
| SCHEMBL2617870 | 0.91 | CCNC (0.42) | ARSIRT6TMEM97HDAC3HDAC1 | |
| SCHEMBL15354106 | 0.89 | SIRT6 (0.40) | ARSIRT6TMEM97MAPTMAPK1 | |
| SCHEMBL13808938 | 0.89 | SIRT6 (0.40) | ARSIRT6TMEM97MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | AR 4346/4885SIRT6 1479/4885TMEM97 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.